Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NetEase Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while NetEase Inc trades at $131.66 (market cap $84.43B). The key difference: NetEase Inc is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and NetEase Inc pays a 2.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NTES | |
|---|---|---|
Market Cap | $39.89B | $84.43B |
Sector | Health | Media |
52-Week High | $491.22 | $159.34 |
52-Week Low | $278.09 | $109.26 |
Enterprise Value | $38.15B | $60.90B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NetEase (NTES) trades at $128.03, down 4.39% today, with strong fundamentals including 29.84% net income margin and $33.76B net income for 2025. The stock shows bullish technical signals with moving averages supporting upside, while RSI indicates potential overbought conditions. Recent Q1 2026 earnings beat expectations with $2.53 EPS versus $2.19 expected, demonstrating continued operational strength.
Wall Street maintains strong bullish sentiment with 82% buy ratings and 34.7% upside potential to analyst targets. Key risks include China market exposure and competitive gaming industry dynamics, but the company's $137.58B cash position and expanding international revenue provide solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
